title: [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
abstract: BACKGROUND
  The majority of patients with juvenile idiopathic arthritis (JIA) need specialized care when they enter adulthood. An increasing number of these patients take biologic disease modifying antirheumatic drugs (DMARDs) at the time of transition. The biologic register BiKeR provides information about the health status and healthcare situation of JIA patients during childhood and adolescence and with their entrance into adulthood these patients are systematically transferred to JuMBO, the follow-up register for young adults with JIA treated with biologics and nonbiologic DMARDs.
  
  
  OBJECTIVE
  The aim of this study was to investigate the healthcare situation of patients with JIA during transition from pediatric to adult care.
  
  
  METHODS
  The current analyses included patients who were successfully transferred from the BiKeR to JuMBO registers. The DMARD treatment and patient-reported outcome (i.e. disease activity, pain and functional ability) were assessed at the last documentation in BikeR and at the first as well as the last documentation in JuMBO.
  
  
  RESULTS
  During the transition period 1 in 10 JIA patients stopped DMARD therapy and 1 in 20 patients did not visit a physician for adults. Three-quarters of the adult JIA patients included in JuMBO (N = 811) reached adult rheumatology care. Adult rheumatologists usually continued therapy with biologics in these patients. Every second patient was still being treated with etanercept, 5 years after the start of the first treatment with biologics. Adult rheumatologists changed the biologic substance in every fourth patient, mainly because of treatment failure. In comparison to patients in regular adult rheumatology care, those who did not remain in specialized care had a higher discontinuation rate of biologics. Moreover, patients with sporadic use of medical care had a significantly poorer health status than those with a regular use of medical care at least every 6 months.
  
  
  CONCLUSIONS
  The data show that there is a need for improving healthcare during the period of transition from pediatric to adult rheumatology.
authors.affiliation: Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland, niewerth@drfz.de.
authors.forename: M
authors.initials: M
authors.lastname: Niewerth
authors.forename: K
authors.initials: K
authors.lastname: Minden
authors.forename: J
authors.initials: J
authors.lastname: Klotsche
authors.forename: G
authors.initials: G
authors.lastname: Horneff
mesh_terms: D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000453:epidemiology*; D001688:Biological Products / Q000627:therapeutic use; D017723:Drug Utilization Review; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D010372:Pediatrics / Q000706:statistics & numerical data*; D015995:Prevalence; D012042:Registries; D012219:Rheumatology / Q000706:statistics & numerical data*; D060305:Transition to Adult Care / Q000706:statistics & numerical data*; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
references.citation: Arthritis Rheum. 2011 Oct;63(10):3163-8
references.pmid: 21702011
references.citation: N Engl J Med. 1992 Apr 16;326(16):1043-9
references.pmid: 1549149
references.citation: Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):507-10
references.pmid: 23070828
references.citation: Z Rheumatol. 2013 May;72(4):339-46
references.pmid: 23456365
references.citation: Ann Rheum Dis. 2011 Sep;70(9):1605-12
references.pmid: 21623000
references.citation: Rheumatology (Oxford). 2013 Oct;52(10):1905-13
references.pmid: 23873820
references.citation: Rheumatol Int. 2014 Aug;34(8):1053-7
references.pmid: 24162563
references.citation: Arthritis Rheum. 2011 Sep;63(9):2809-18
references.pmid: 21560116
references.citation: Arthritis Rheum. 2012 Jul;64(7):2366-74
references.pmid: 22231288
references.citation: Clin Exp Rheumatol. 2006 Sep-Oct;24(5):499-507
references.pmid: 17181917
references.citation: Rheumatology (Oxford). 2012 Aug;51(8):1407-15
references.pmid: 22447885
references.citation: Arthritis Rheum. 2003 Mar;48(3):767-75
references.pmid: 12632431
references.citation: Arthritis Rheum. 2009 Aug 15;61(8):1077-86
references.pmid: 19644903
references.citation: Ann Rheum Dis. 2013 Dec;72(12):1983-8
references.pmid: 23256951
references.citation: Ann Rheum Dis. 2004 Dec;63(12):1638-44
references.pmid: 15115709
references.citation: Rheumatology (Oxford). 2010 Jan;49(1):116-22
references.pmid: 19926670
references.citation: Front Pharmacol. 2011 Oct 10;2:60
references.pmid: 22013422
references.citation: Arthritis Rheum. 2002 Sep;46(9):2392-401
references.pmid: 12355487
references.citation: Rheumatology (Oxford). 2013 Nov;52(11):1999-2003
references.pmid: 23893666